Skip to main content
Download PDF

Brainstem atrophy in dementia with Lewy bodies compared with progressive supranuclear palsy and Parkinson’s disease on MRI

BMC Neurology volume 23, Article number: 114 (2023) Cite this article

Abstract

Background

Although Dementia with Lewy bodies (DLB) is the second most common form of dementia in elderly patients, it remains underdiagnosed compared with Alzheimer's (AD) and Parkinson's diseases (PD). This may be explained by overlapping clinical symptoms, e.g. Parkinsonism. While current MRI research focuses primarily on atrophy patterns of the frontal and temporal lobes, we focus on brainstem characteristics of DLB. In particular, we focused on brainstem atrophy patterns distinguishing DLB from Progressive Supranuclear Palsy (PSP) and PD based as the most common differential diagnoses.

Methods

We identified patients diagnosed with DLB, PD, PSP, and a control group (CTRL) in our psychiatric and neurological archives. All patients with competing diagnoses and without a high-quality T1 MPRAGE 3D dataset were excluded. We assessed atrophy patterns in all patients (1) manually and (2) using FastSurfer’s segmentation algorithm in combination with FreeSurfer’s brainstem volumetric calculations. We compared classical measurement methods and ratios with automated volumetric approaches.

Results

One hundred two patients were enrolled and evaluated in this study. Patients with DLB (n = 37) showed on average less atrophy of the brainstem than patients with PSP (n = 21), but a significantly more pronounced atrophy than patients with PD (n = 36) and the control group (CTRL, n = 8). The mean measured sagittal diameters of the midbrain were 8.17 ± 1.06 mm (mean ± standard deviation) for PSP, 9.45 ± 0.95 mm for DLB, 10.37 ± 0.99 mm for PD and 10.74 ± 0.70 for CTRL. The mean measured areas of the midbrain were 81 ± 18 mm2 for PSP, 105 ± 17 mm2 for DLB, 130 ± 26 mm2 for PD and 135 ± 23 mm2 for CTRL. The mean segmented volumes of the midbrain were 5595 ± 680 mm3 for PSP, 6051 ± 566 mm3 for DLB, 6646 ± 802 mm3 for PD and 6882 ± 844 mm3 for CTRL. The calculated midbrain pons ratios did not show superiority over the absolute measurements of the midbrain for distinguishing PSP from DLB. Because of the relatively uniform atrophy throughout the brainstem, the ratios were not suitable for distinguishing DLB from PD.

Conclusions

DLB patients exhibit homogenous atrophy of the brainstem and can be distinguished from patients with PSP and PD by both manual measurement methods and automated volume segmentation using absolute values or ratios.

Peer Review reports

Introduction

Neurodegenerative diseases especially dementias show a strongly increasing prevalence in an ageing population, that reduce the quality of life of affected persons and their caregivers and create a significant economic burden [1]. Although Dementia with Lewy bodies (DLB) is the second most common form of dementia in elderly patients, it remains underdiagnosed [2]. This is probably due to the numerous clinical overlaps with other neurodegenerative diseases displaying dementia in the course, especially Alzheimer’s disease (AD) and Parkinson’s disease (PD). DLB is characterized by dementia, progressive deficits in visual spatial abilities and frontal executive functions and further clinical core features of parkinsonism, visual hallucinations and fluctuations of alertness [3]. Early and correct diagnosis is essential to ensure optimal treatment and to avoid unwanted effects from dopamine blocking agents for which DLB patients have a very high sensitivity [1]. To increase diagnostic accuracy and monitor potential therapeutic drug effects in clinical trials, there is a need to widen the research for reliable and validated biomarkers. Several biomarkers are available to improve diagnostic accuracy in DLB [4] including the atrophy patterns in Magnetic Resonance imaging (MRI). While current MRI research focuses primarily on structures of the frontal and temporal lobes [5], we would like to shed light on the atrophy patterns of the brainstem here. In particular, we are interested in how DLB fits in between the commonly studied atrophy patterns of progressive supranuclear palsy (PSP) and PD, two differential diagnoses known to affect brainstem integrity [6, 7]. Several widely used measurement methods are already available for PSP, such as the Midbrain-To-Pons-Ratio [7], the Midbrain-To-Pons-Area-Ratio [8], the Magnetic resonance parkinsonism index (MRPI) [9,10,11] or the MRPI 2.0 [12] but data for DLB is generally lacking. To fill in this gap, we applied automated segmentation and volumetric measurements of the brainstem in DLB, PD and PSP to assess their ability to facilitate the diagnosis and improve diagnostic confidence.

Methods

Participant’s population

An available high quality MRI brain scan with a 3D T1 MPRAGE dataset was the key inclusion criterion in this retrospective observational study including data from 01/01/2012 to 12/31/2021.

We analyzed patients from the psychiatric archives with clinically confirmed DLB according to the Fourth consensus report of the DLB Consortium, rated by an experienced psychiatrist (NH) [4].

Patients with confirmed PSP or PD were collected from the neurological archives, including all available clinical data. Diagnosis was reassessed by three movement disorder specialists (CvR, FM, MB) rating the diagnostic criteria for PSP according to Höglinger et al. [13]. PD patients were diagnosed according to UK Brain Bank and Movement Disorders Society criteria [14]. We only included subjects with PSP-RS (Richardson’s syndrome) into this analysis to increase diagnostic accuracy and reduce clinical heterogeneity in the PSP group.

The control group consisted of patients without neurological or psychiatric diseases and with a similar age and sex distribution. Exclusion criteria were large microvascular lesions (Fazekas score [15] of 2 or more) and a global cortical atrophy (GCA score [16] of 2 or more). We identified control patients using the database search of our Picture Archiving and Communication System (PACS) and confirmed them using physician letters and diagnostic findings.

MRI analysis

3D T1 data sets were acquired with two different MRI scanners (1.5 Tesla Siemens AvantoFit and 3.0 Tesla Siemens Magnetom/PrismaFit). We included only patients with T1 MP-RAGE (Magnetization Prepared—RApid Gradient Echo) sequences. Patients who had only T1 VIBE (Volumetric interpolated breath-hold examination) sequences were excluded because of the lower contrast between white and grey matter.

All subjects were scanned in sagittal orientation with a voxel resolution of 1.0 × 1.0 × 1.0 mm (parameters for 1.5 T MP-RAGE: scan time 298 s, TR 1.700 ms, TE 2.460 ms, flip angle 8°, TI 900 ms, 3.0 T: scan time 260 s, TR 2.000 ms, TE 2.980 ms, flip angle 9°, TI 900 ms; and for 3.0 T MP-RAGE: scan time 260 s, TR 2.000 ms, TE 2.980 ms, flip angle 9°, TI 900 ms).

We retrospectively analyzed MRIs with FastSurfer/FreeSurfer and three independent raters blinded to diagnosis. The raters were radiologists with 5 years (rater 1, EK), 6 years (rater 2, AJ) and 4 years (rater 3, SM) of experience in neuroradiologic MR imaging of dementia.

Automated volumetric MRI analysis

In the first step, we used the 3D Slicer Software (Version 4.10.2, https://www.slicer.org/) to convert the DICOM (Digital Imaging and Communications in Medicine) file format to the NIFTI (Neuroimaging Informatics Technology Initiative) file format. For segmentation, FastSurfer [17] was used (Version commit dabf1e02e6253cac8bd3d641958b01e5348ea0e7, https://github.com/Deep-MI/FastSurfer/commit/dabf1e02e6253cac8bd3d641958b01e5348ea0e7) with the procedure call: run_FastSurfer.sh –fs_license $FREESURFER _HOME/license.txt –sd $out_path –sid $filename –t1 $f/$filename.nii –parallel –threads 24 –batch 64 –order 3 –vol_segstats. Surface statistics were obtained via FMRIB Software Library v6.0 (FSL 6.0), Version 6.0.4, from https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FslInstallation recon_surf). Used graphic card was GPU nVidia GV100, Driver 455.45.01, CUDA Version 11.1. Operating sytem was Ubuntu 18.04.5 LTS. Data from each patient’s stats folder was stored in a separate Excel-file. After visual control of the FastSurfer segmentation, we executed FreeSurfer’s brainstem script [18, 19]. For each segmentation, the volumes of medulla oblongata, pons, superior cerebellar peduncle, midbrain and the whole brainstem were analyzed and controlled visually for correctness. An example of the segmented areas is shown in Fig. 1A. The average computation time for the entire procedure was 20 min (8 min for the segmentation and 12 min for the brainstem script).

Fig. 1
figure 1

Illustration of automated (A) and manual (B, C) measurements. Legend: A FastSurfer’s segmentation with FreeSurfer’s brainstem script of midbrain (orange), pons (pink), medulla oblongata (purple) and superior cerebellar peduncle (yellow), visualized using 3D slicer. B Drawn ellipsoids of midbrain (1) and pons (2), for the measurements of the diameters. C Manual area segmentation on sagittal plane of midbrain (orange) and pons (pink)

Full size image

Manual metric MRI analysis

Each rater separately and without knowledge of patient information measured the diameter and area of the midbrain and pons according to the calculation of the midbrain-to-pons-ratio (using elliptical regions of interest) [7], and the midbrain-to-pons-area-ratio [8], respectively. The software used was GE Centricity RA1000 (GE Healthcare, Chicago, Illinois, USA). An example of the measurements is shown in Fig. 1B, C.

Statistical analysis

We used the Statistica program, version 13 (TIBCO Software Inc., Palo Alto, CALIFORNIA, USA). The significance level was set at P < 0.05. Interrater agreement was assessed by calculating the intraclass correlation coefficient (ICC, type: two-way, absolute agreement) for the measurements [20]. The latter was calculated using the libraries of r Version 4 (https://www.r-project.org/): irr, readxl, lpSolve and psych. Values were interpreted according to Koo and Li [21]. An ANOVA (analysis of variance) posthoc analysis was done with Tukey’s Test [22] in r.

Receiver-operating-characteristics (ROC) with area-under-curve calculations and Youden’s J analyses were used to estimate the optimal thresholds to discriminate the groups. We used the t-test to detect significant differences in the distribution or median.

Corrections for multiple comparisons were performed with the Bonferroni method [23].

Results

Participants

We were able to confirm the diagnosis of DLB according to the Fourth consensus report of the DLB Consortium [4] in a group of 110 patients with DLB from our psychiatric archives. In our neurological archives, we found 48 patients with PSP and 184 patients with PD. We excluded 69 patients with DLB, 18 patients with PSP, and 122 patients with PD due to an insufficient MRI (missing T1 MPRAGE or movement artifacts). Four DLB, Nine PSP and 26 PD patients were excluded because of a competing differential diagnosis. Finally, 37 patients with DLB, 21 patients with PSP, 36 patients with PD and 8 control patients (3 women, 67.2 ± 9.3 years) were included. A flowchart of included patients and a pie chart of distributed diseases are shown in Figs. 2 and 3, respectively.

Fig. 2
figure 2

Flowchart of included patients. Legend: DLB—Dementia with Lewy bodies; PSP – progressive supranuclear palsy; PD – Parkinson’s disease

Full size image
Fig. 3
figure 3

Pie chart of diseases and controls. Legend: PSP—progressive supranuclear palsy; DLB—dementia with Lewy bodies; PD—Parkinson’s disease; CTRL – control group

Full size image

Clinical data

The mean disease duration at the time of MR scan was 2.9 ± 2.4 years in patients with PSP (n = 21, 7 females, 72.1 ± 6.5 year), 2.8 ± 2.6 years in patients with DLB (n = 37, 18 women, mean age ± standard deviation: 75.4 ± 7.7 years) and 2.6 ± 2.4 years in patients with PD (n = 36, 14 women, 68.3 ± 10.2 years).

In patients with DLB, the last documented Mini–Mental State Examination (MMSE) before MRI was 21.7 ± 5.8 points. In PD patients, mean Hoehn and Yahr score [24] was 2.3 ± 1.0. A subgroup of six patients (mean age 77.1 ± 6.9 years) suffered from Parkinson’s disease dementia (PDD).

Automated volumetric MRI analysis

The mean segmented volumes of the midbrain were 5595 ± 680 mm3 for PSP, 6051 ± 566 mm3 for DLB, 6646 ± 802 mm3 for PD, and 6882 ± 844 mm3 for the control group. Volumes differed significantly between the PSP and DLB group, t-test, p < 0.01, the PSP and PD group, t-test, p < 0.001, and between DLB and PD, t-test, p < 0.003. There were no significant differences between PD and the control group (t-test, p > 0.5).

The mean values of all volumes are shown in Table 1. A boxplot of the absolute volumes of the midbrain and whole brainstem is shown in Fig. 4A and D.

Table 1 Manual and volumetric analysis of selected structures
Full size table
Fig. 4
figure 4

Box charts of the measured and segmented absolute values. Legend: PSP—progressive supranuclear palsy; DLB—dementia with Lewy bodies; PD—Parkinson’s disease; CTRL – control group

Full size image

In the subgroup of patients with PDD, the mean segmented volume of the midbrain was 6286 ± 1081 mm3.

Manual measurements

Mean measured midbrain diameters were 8.17 ± 1.06 mm (mean ± standard deviation) for PSP, 9.45 ± 0.95 mm for DLB, 10.37 ± 0.99 mm for PD, and 10.74 ± 0.70 for the control group. T-tests demonstrated significant differences between all groups, with the exception of the comparison of PD and the control group with p = 0.18.

The mean measured areas of the midbrain were 81 ± 18 mm2 for PSP, 105 ± 17 mm2 for DLB, 130 ± 26 mm2 for PD, and 135 ± 23 mm2 for CTRL. T-test demonstrated similar results as above. The p-values of pairwise t-tests are shown in Table 2. To confirm the results, we performed an additional analysis of variance (ANOVA) post hoc, which is presented in Table 3.

Table 2 Results of paired t-Test’s for measured diameters, areas and volumes
Full size table
Table 3 Results (p-values) of Tukey’s test (ANOVA post hoc) for six pairwise comparisons of four groups
Full size table

In the subgroup of patients with PDD, the mean measured midbrain diameter and area were 10.2 ± 8 mm and 122 ± 18 mm2, respectively.

Figure 4B and C demonstrate a boxplot of the measured diameters and volumes.

Interrater reliability

The single score intraclass correlation’s (3 raters, type agreement) were ICC(A,1) = 0.84 for the diameter (good reliability) and ICC(C,1) = 0.92 for the area measurements (excellent reliability).

Differentiating of groups

The best combined marker for the differentiation of PSP, DLB and PD using Youden’s J analyses of Area-under-curve was the measured midbrain area with an optimal threshold of 94 mm2 for differentiation of PSP and DLB (ROC AUC 0.83, sensitivity 86%, specificity 60%) and 117 mm2 for DLB vs. PD (ROC AUC 0.79, sensitivity 73%, specificity 69%).

The thresholds for the measured brainstem diameter in the sagittal plane were 8.6 mm for differentiation of PSP and DLB (ROC AUC 0.82, sensitivity 67%, specificity 84%), and 9.6 mm for DLB vs. PD (ROC AUC 0.75, sensitivity 65%, specificity 75%).

The diameter ratio demonstrated a sensitivity of 87% and specificity of 77% in distinguishing PSP and DLB with at a threshold of 0.524 (ROC AUC 0.86). The area ratio performed second best a sensitivity of 76% and a specificity of 88% at a threshold of 0.17 (ROC AUC 0.85). The volume ratio (midbrain:pons) performed worst with a sensitivity of 76% and specificity of 78% at a ratio of 0.422 (ROC AUC 0.80). The use of the additional volume ratio (midbrain + superior cerebellar peduncle:pons) minimally improved sensitivity and specificity (ROC AUC 0.81). Because of the relatively uniform atrophy of the entire brainstem, the ratios were inappropriate for distinguishing DLB from PD. Figure 5 demonstrates a boxplot of the calculated ratios. The mean calculated ratios in the subgroup of patients with PDD were 0.61 ± 0.06 (diameter), 0.24 ± 0.04 (area) and 0.43 ± 0.04 (volume).

Fig. 5
figure 5

Box charts of the calculated ratios. Legend: PSP—progressive supranuclear palsy; DLB—dementia with Lewy bodies; PD—Parkinson’s disease; CTRL – control group

Full size image

Patients with DLB showed less atrophy than patients with PSP in all measured and calculated brainstem parameters, but significantly more pronounced atrophy than patients with PD and the control group.

Discussion

Brainstem atrophy in DLB is less analyzed and poorly understood compared to other Parkinsonian disorders, though several symptoms indicate underlying brainstem pathologies [25]. Brainstem atrophy pattern are well studied in PSP and PD, including the cerebellum in PSP [26]. On the contrary, for other neurodegenerative diseases, like DLB, there are only a few studies, for example on the non-fluent primary progressive aphasias, available [27]. Therefore, we assessed brainstem parameters in DLB patients on MRI. The group of 102 patients comprised of DLB (37) and PSP (21), PD (36) and non-neurological subjects as controls. We applied state of the art segmentation algorithms and brainstem volumetric calculations by implementing the FreeSurfer brainstem script on FastSurfer segmentation, with an absolute calculation time of approx. 20 min per patient. Thus, we were able to demonstrate moderate brainstem atrophy in DLB patients, which can be classified between the pronounced atrophy in PSP and the non-significant atrophy in PD patients.

Comparison with classical brainstem measurements showed a general agreement of volumetric results with a slightly worse sensitivity and specificity. We could show that manual measurements and automated volumetric calculations can be helpful not only in the differential diagnostics of PD, PSP and Multiple System Atrophy, as already known [28], but also of DLB. Since automated categorization methods are already available for PD, PD and MSA in clinical settings [29], symptom-based interpretation of measured and volumetric results may also improve diagnostic confidence in DLB.

By showing significant differences between PSP and PD, our results are consistent with previous MRI studies, analyzing brainstem atrophy [30, 31], as well as with combined MRI and pathologic studies [32].

For future studies, it would be particularly interesting to assess longitudinal data by evaluating atrophy progression in DLB over time, as it has been demonstrated to distinguish PSP from PD based on 1-year decline in midbrain-to-pons ratio [33].

The additional use of further imaging and non-imaging biomarkers could also be helpful here. Other MRI-based clinical radiological correlations have already been demonstrated to distinguish PSP, MSA-P, and PD [34] and for PSP, early diagnostic accuracy could be improved using a combination of cerebrospinal fluid (CSF) tau ratio and brainstem atrophy [35].

Further, atrophy patterns in the frontal and temporal regions could support the diagnosis of DLB [5, 36]. Quantitative MRI measurements could expand the spectrum with newly developed high-resolution T1 or T2 mappings [37,38,39,40,41,42], by recognizing and measuring pathologic white matter changes.

Limitations

Usage of an automated web-based MPRI calculation [43] was not possible for data protection reasons.

Another limitation is that we did not compare our groups with patients with multiple system atrophy [44], also an important but rare differential diagnosis, because we could not include enough patients.

Conclusion

DLB patients exhibit a homogenous atrophy pattern of the brainstem and can be distinguished from patients with PSP and PD by both manual measurement methods and automated volume segmentation. The midbrain-pons-ratios are well suited to distinguish PSP and DLB, but not DLB and PD.

Availability of data and materials

The datasets used and analyzed in the current study are available from the corresponding author upon request. Individual patient data were not published, so no identification can be made.

Abbreviations

ANOVA:

Analysis of variance

AUC:

Area under curve

cMRI:

Cranial magnetic resonance imaging

CTRL:

Control group

DLB:

Dementia with Lewy bodies

ICC:

Interclass correlation coefficient

MCI:

Mild cognitive impairment

MR:

Magnetic resonance

PD:

Parkinson’s disease

PSP:

Progressive supranuclear palsy

ROC:

Receiver operating characteristics

SD:

Standard deviation

MP-RAGE:

Magnetization Prepared—RApid Gradient Echo

VIBE:

Volumetric interpolated breath-hold examination

References

  1. Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. The Lancet. 2015;386:1683–97.

    Article  Google Scholar 

  2. Vann Jones SA, O’Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2014;44:673–83.

    Article  CAS  PubMed  Google Scholar 

  3. Geser F, Wenning GK, Poewe W, McKeith I. How to diagnose dementia with Lewy bodies: State of the art. Mov Disord. 2005;20:S11-20.

    Article  PubMed  Google Scholar 

  4. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89:88–100.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Khadhraoui E, Müller SJ, Hansen N, Riedel CH, Langer P, Timäeus C, et al. Manual and automated analysis of atrophy patterns in dementia with Lewy bodies on MRI. BMC Neurol. 2022;22:114.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Jubault T, Brambati SM, Degroot C, Kullmann B, Strafella AP, Lafontaine AL, et al. Regional brain stem atrophy in idiopathic Parkinson’s disease detected by anatomical MRI. PLoS One. 2009;4:e8247.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Massey LA, Jager HR, Paviour DC, O’Sullivan SS, Ling H, Williams DR, et al. The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology. 2013;80:1856–61.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Oba H, Yagishita A, Terada H, Barkovich AJ, Kutomi K, Yamauchi T, et al. New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology. 2005;64:2050–5.

    Article  CAS  PubMed  Google Scholar 

  9. Quattrone A, Nicoletti G, Messina D, Fera F, Condino F, Pugliese P, et al. MR Imaging Index for Differentiation of Progressive Supranuclear Palsy from Parkinson Disease and the Parkinson Variant of Multiple System Atrophy. Radiology. 2008;246:214–21.

    Article  PubMed  Google Scholar 

  10. Morelli M, Arabia G, Salsone M, Novellino F, Giofrè L, Paletta R, et al. Accuracy of magnetic resonance parkinsonism index for differentiation of progressive supranuclear palsy from probable or possible Parkinson disease: MR Imaging and Parkinson’s Disease. Mov Disord. 2011;26:527–33.

    Article  PubMed  Google Scholar 

  11. Morelli M, Arabia G, Novellino F, Salsone M, Giofre L, Condino F, et al. MRI measurements predict PSP in unclassifiable parkinsonisms: a cohort study. Neurology. 2011;77:1042–7.

    Article  CAS  PubMed  Google Scholar 

  12. Quattrone A, Morelli M, Nigro S, Quattrone A, Vescio B, Arabia G, et al. A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson’s disease. Parkinsonism Relat Disord. 2018;54:3–8.

    Article  PubMed  Google Scholar 

  13. Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria: MDS Clinical Diagnostic Criteria for PSP. Mov Disord. 2017;32:853–64.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord Off J Mov Disord Soc. 2015;30:1591–601.

    Article  Google Scholar 

  15. Fazekas F, Chawluk J, Alavi A, Hurtig H, Zimmerman R. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. Am J Roentgenol. 1987;149:351–6.

    Article  CAS  Google Scholar 

  16. Pasquier F, Leys D, Weerts JGE, Mounier-Vehier F, Barkhof F, Scheltens P. Inter-and Intraobserver Reproducibility of Cerebral Atrophy Assessment on MRI Scans with Hemispheric Infarcts. Eur Neurol. 1996;36:268–72.

    Article  CAS  PubMed  Google Scholar 

  17. Henschel L, Conjeti S, Estrada S, Diers K, Fischl B, Reuter M. FastSurfer - A fast and accurate deep learning based neuroimaging pipeline. Neuroimage. 2020;219:117012.

    Article  PubMed  Google Scholar 

  18. Iglesias JE, Van Leemput K, Bhatt P, Casillas C, Dutt S, Schuff N, et al. Bayesian segmentation of brainstem structures in MRI. Neuroimage. 2015;113:184–95.

    Article  PubMed  Google Scholar 

  19. Fischl B. FreeSurfer NeuroImage. 2012;62:774–81.

    Article  PubMed  Google Scholar 

  20. Shrout PE, Fleiss JL. Intraclass correlations: Uses in assessing rater reliability. Psychol Bull. 1979;86:420–8.

    Article  CAS  PubMed  Google Scholar 

  21. Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med. 2016;15:155–63.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Tukey JW. Comparing Individual Means in the Analysis of Variance. Biometrics. 1949;5:99.

    Article  CAS  PubMed  Google Scholar 

  23. Haynes W. Bonferroni Correction. In: Dubitzky W, Wolkenhauer O, Cho KH, Yokota H, editors. Encyclopedia of Systems Biology. New York, NY: Springer New York; 2013. p. 154–154.

    Chapter  Google Scholar 

  24. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17:427–427.

    Article  CAS  PubMed  Google Scholar 

  25. Seidel K, Mahlke J, Siswanto S, Krüger R, Heinsen H, Auburger G, et al. The Brainstem Pathologies of Parkinson’s Disease and Dementia with Lewy Bodies: The Brainstem in iPD and DLB. Brain Pathol. 2015;25:121–35.

    Article  PubMed  Google Scholar 

  26. Lee Y, Lee DK, Lee JM, Chung SJ, Lee JJ, Sohn YH, et al. Volumetric analysis of the cerebellum in patients with progressive supranuclear palsy. Eur J Neurol. 2017;24:212–8.

    Article  CAS  PubMed  Google Scholar 

  27. Silsby M, Tweedie-Cullen RY, Murray CR, Halliday GM, Hodges JR, Burrell JR. The midbrain-to-pons ratio distinguishes progressive supranuclear palsy from non-fluent primary progressive aphasias. Eur J Neurol. 2017;24:956–65.

    Article  CAS  PubMed  Google Scholar 

  28. Sjöström H, Granberg T, Hashim F, Westman E, Svenningsson P. Automated brainstem volumetry can aid in the diagnostics of parkinsonian disorders. Parkinsonism Relat Disord. 2020;79:18–25.

    Article  PubMed  Google Scholar 

  29. Chougar L, Faouzi J, Pyatigorskaya N, Yahia-Cherif L, Gaurav R, Biondetti E, et al. Automated Categorization of Parkinsonian Syndromes Using Magnetic Resonance Imaging in a Clinical Setting. Mov Disord. 2021;36:460–70.

    Article  CAS  PubMed  Google Scholar 

  30. Slowinski J, Imamura A, Uitti RJ, Pooley RA, Strongosky AJ, Dickson DW, et al. MR imaging of brainstem atrophy in progressive supranuclear palsy. J Neurol. 2008;255:37–44.

    Article  PubMed  Google Scholar 

  31. Kim BC, Choi SM, Choi KH, Nam TS, Kim JT, Lee SH, et al. MRI measurements of brainstem structures in patients with vascular parkinsonism, progressive supranuclear palsy, and Parkinson’s disease. Neurol Sci. 2017;38:627–33.

    Article  PubMed  Google Scholar 

  32. Paviour DC, Price SL, Stevens JM, Lees AJ, Fox NC. Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy. Neurology. 2005;64:675–9.

    Article  CAS  PubMed  Google Scholar 

  33. Kannenberg S, Caspers J, Dinkelbach L, Moldovan A-S, Ferrea S, Südmeyer M, et al. Investigating the 1-year decline in midbrain-to-pons ratio in the differential diagnosis of PSP and IPD. J Neurol. 2021;268:1526–32.

    Article  PubMed  Google Scholar 

  34. Paviour DC, Price SL, Jahanshahi M, Lees AJ, Fox NC. Regional brain volumes distinguish PSP, MSA-P, and PD: MRI-based clinico-radiological correlations: MRI-Based Clinico-Radiological Correlations. Mov Disord. 2006;21:989–96.

    Article  PubMed  Google Scholar 

  35. Borroni B, Malinverno M, Gardoni F, Grassi M, Parnetti L, Agosti C, et al. A Combination of CSF Tau Ratio and Midsaggital Midbraintopons Atrophy for the Early Diagnosis of Progressive Supranuclear Palsy. J Alzheimers Dis. 2010;22:195–203.

    Article  CAS  PubMed  Google Scholar 

  36. Hansen N, Müller SJ, Khadhraoui E, Riedel CH, Langer P, Wiltfang J, et al. Metric magnetic resonance imaging analysis reveals pronounced substantia-innominata atrophy in dementia with Lewy bodies with a psychiatric onset. Front Aging Neurosci. 2022;14:815813.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Baudrexel S, Nürnberger L, Rüb U, Seifried C, Klein JC, Deller T, et al. Quantitative mapping of T1 and T2* discloses nigral and brainstem pathology in early Parkinson’s disease. Neuroimage. 2010;51:512–20.

    Article  PubMed  Google Scholar 

  38. Eminian S, Hajdu SD, Meuli RA, Maeder P, Hagmann P. Rapid high resolution T1 mapping as a marker of brain development: Normative ranges in key regions of interest. PLoS One. 2018;13:e0198250.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Wang X, Roeloffs V, Merboldt KD, Voit D, Schätz S, Frahm J. Single-shot Multi-slice T1 Mapping at High Spatial Resolution – Inversion-Recovery FLASH with Radial Undersampling and Iterative Reconstruction. Open Med Imaging J. 2015;9:1–8.

    Article  Google Scholar 

  40. Jiang K, Zhu Y, Jia S, Wu Y, Liu X, Chung YC. Fast T1 mapping of the brain at high field using Look-Locker and fast imaging. Magn Reson Imaging. 2017;36:49–55.

    Article  PubMed  Google Scholar 

  41. McCreary CR, Salluzzi M, Andersen LB, Gobbi D, Lauzon L, Saad F, et al. Calgary Normative Study: design of a prospective longitudinal study to characterise potential quantitative MR biomarkers of neurodegeneration over the adult lifespan. BMJ Open. 2020;10:e038120.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Müller SJ, Khadhraoui E, Voit D, Riedel CH, Frahm J, Ernst M. First clinical application of a novel T1 mapping of the whole brain. Neuroradiol J. 2022. https://doi.org/10.1177/197140092210842.

  43. Nigro S, Antonini A, Vaillancourt DE, Seppi K, Ceravolo R, Strafella AP, et al. Automated MRI Classification in Progressive Supranuclear Palsy: a Large International Cohort Study. Mov Disord. 2020;35:976–83.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Paviour DC, Price SL, Jahanshahi M, Lees AJ, Fox NC. Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain. 2006;129:1040–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Prof. Dr. Jens Wiltfang is supported by an Ilídio Pinho professorship, iBiMED (UIDB/04501/2020) at the University of Aveiro, Portugal.

We thank Prof. Dr. Martin Reuter (DZNE – Deutsches Zentrum für Neurodegenerative Erkrankungen) for his help and answering questions about the compatibility between FastSurfer and FreeSurfer.

Funding

Open Access funding enabled and organized by Projekt DEAL. No funding was received for the conduct of this study. The authors gratefully acknowledge the support of publication fees by the Deutsche Forschungsgemeinschaft and the Open Access Publication Fund of the University of Göttingen.

Author information

Authors and Affiliations

  1. Institute of Diagnostic and Interventional Neuroradiology, University Medical Center Göttingen (UMG), Georg-August-University Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany

    Sebastian Johannes Müller, Eya Khadhraoui, Ala Jamous, Philip Langer, Christian Heiner Riedel & Marielle Ernst

  2. Department of Psychiatry and Psychotherapy, University Medical Center Göttingen (UMG), Georg-August-University, Göttingen, Germany

    Niels Hansen, Jens Wiltfang & Claudia Lange

  3. German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany

    Jens Wiltfang & Christoph van Riesen

  4. Department of Medical Sciences, Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), University of Aveiro, Aveiro, Portugal

    Jens Wiltfang

  5. Department of Nuclear Medicine, University Medical Center Göttingen (UMG), Georg-August-University, Göttingen, Germany

    Caroline Bouter

  6. Department of Neurology, University Medical Center Göttingen (UMG), Georg-August-University, Göttingen, Germany

    Christoph van Riesen, Fabian Maass & Michael Bartl

Authors
  1. Sebastian Johannes Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eya Khadhraoui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Niels Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ala Jamous
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Philip Langer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jens Wiltfang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Christian Heiner Riedel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Caroline Bouter
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Christoph van Riesen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Fabian Maass
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Michael Bartl
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Claudia Lange
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Marielle Ernst
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors have reviewed and approved the submitted manuscript for publication. SM and ME were the project administrators and organized the data curation, measurements, and design. EK, ME, NH and SM wrote the manuscript. PL and SM administrated FastSurfer/FreeSurfer and made the volumetric measurements. SM, EK and AJ contributed to data collection, measurements and analysis. CL and ME contributed to the conceptualization, literature review, and design of the study. CR and JW contributed to the formal analysis of the study and edited the manuscript. CvR, FM, CB and MB reassessed the diagnoses of all PSP and PD patients. The authors agree to be accountable for all aspects of the work and to ensure integrity and accuracy.

Corresponding author

Correspondence to Marielle Ernst.

Ethics declarations

Ethics approval and consent to participate

This study was ethically approved by the institutional review board of the University Medical Center Göttingen (No. 16/04/2022, “Ethics Committee of the University of Göttingen”, Von-Siebold-Str. 4, 37075 Göttingen, Germany) and adhered to the 2013 Helsinki Declaration.

Due to the retrospective, observational nature of the study, the ethics committee (“Ethics Committee of the University of Göttingen”) waived the need for informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests. JW is an advisory board member of Abbott, Biogen, Boehringer Ingelheim, Immunogenetics, Lilly, MSD Sharp & Dohme, and Roche Pharma. JW received honoraria for lectures from the AGNP, Actelion, Amgen, Beeijing Yibai Science and Technology Ltd., CSF-Society, Helios Klinikum Wuppertal, Janssen Cilag, Med Update GmbH, Pfizer, Roche Pharma, and Vitos Kurhessen-Bad Emstal. JW holds the following patents: PCT/EP 2011 001724 and PCT/EP 2015 052945, MB has received funding from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – 413501650. FM received speaker honoraria from BIAL and Abbvie. CvR speaker honoraria/counseling for Abbvie and Zambon.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Müller, S.J., Khadhraoui, E., Hansen, N. et al. Brainstem atrophy in dementia with Lewy bodies compared with progressive supranuclear palsy and Parkinson’s disease on MRI. BMC Neurol 23, 114 (2023). https://doi.org/10.1186/s12883-023-03151-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12883-023-03151-4

Keywords

BMC Neurology

ISSN: 1471-2377

Contact us